| Diabetes Mellitus, Non-Insulin-Dependent

Kerendia vs Mounjaro

Side-by-side clinical, coverage, and cost comparison for diabetes mellitus, non-insulin-dependent.

Deep comparison between: Kerendia vs Mounjaro with Prescriber.AI

AI compares prescribing info and payer-specific access barriers across 1,200+ formularies. Here's a preview of what prescribers are already asking.

Safety signalsMounjaro has a higher rate of injection site reactions vs Kerendia based on FDA-approved prescribing information

Coverage gaps3 major payers require step therapy for Mounjaro but not Kerendia, including UnitedHealthcare

Category

Kerendia

Mounjaro

At A Glance

RouteOral

FrequencyOnce daily

ClassMineralocorticoid receptor antagonist

RouteSC injection

FrequencyOnce weekly

ClassGIP/GLP-1 receptor agonist

Indications

Chronic Kidney Diseases
Diabetes Mellitus, Non-Insulin-Dependent
Heart failure
Chronic kidney disease stage 5
Myocardial Infarction

Diabetes Mellitus, Non-Insulin-Dependent

Dosing

Chronic Kidney Diseases, Diabetes Mellitus, Non-Insulin-Dependent Starting dose 10 mg or 20 mg orally once daily based on eGFR and serum potassium; target dose 20 mg once daily, adjusted after 4 weeks based on serum potassium levels.

Heart failure Starting dose 10 mg or 20 mg orally once daily based on eGFR and serum potassium; target dose 20 mg or 40 mg once daily based on eGFR at initiation, adjusted after 4 weeks.

Diabetes Mellitus, Non-Insulin-Dependent Start at 2.5 mg SC once weekly; increase to 5 mg after 4 weeks; escalate in 2.5 mg increments every >=4 weeks as needed; max 15 mg once weekly in adults and 10 mg once weekly in pediatric patients 10 years of age and older.

Contraindications

Hypersensitivity to any component of Kerendia
Concomitant treatment with strong CYP3A4 inhibitors
Adrenal insufficiency

Personal or family history of medullary thyroid carcinoma (MTC) or Multiple Endocrine Neoplasia syndrome type 2 (MEN 2)
Known serious hypersensitivity to tirzepatide or any excipient in MOUNJARO

Drug Interactions

828View drug interactions

299View drug interactions

Adverse Reactions

Most common (>=10%) hyperkalemia

Serious hyperkalemia requiring hospitalization, renal impairment, acute kidney injury, renal failure

Postmarketing angioedema, rash, urticaria

Most common (>=5%) Nausea, diarrhea, decreased appetite, vomiting, constipation, dyspepsia, abdominal pain

Serious Risk of thyroid C-cell tumors, acute pancreatitis, hypoglycemia (with insulin secretagogues or insulin), hypersensitivity reactions, acute kidney injury due to volume depletion, severe gastrointestinal adverse reactions, diabetic retinopathy complications, acute gallbladder disease, pulmonary aspiration

Postmarketing Anaphylaxis, angioedema, acute pancreatitis, hemorrhagic and necrotizing pancreatitis, ileus, intestinal obstruction, severe constipation including fecal impaction, pulmonary aspiration, acute renal failure or worsening of chronic renal failure, alopecia

Pharmacology

Finerenone is a nonsteroidal, selective mineralocorticoid receptor (MR) antagonist that blocks MR-mediated sodium reabsorption and MR overactivation in epithelial (kidney) and nonepithelial (heart, blood vessels) tissues; it has high potency and selectivity for the MR with no relevant affinity for androgen, progesterone, estrogen, or glucocorticoid receptors.

Tirzepatide is a dual GIP and GLP-1 receptor agonist that selectively binds and activates both receptors, enhancing first- and second-phase insulin secretion and reducing glucagon levels in a glucose-dependent manner, thereby lowering fasting and postprandial glucose, decreasing food intake, and reducing body weight.

View Full FDA Information

View full FDA information

Enter your patient's insuranceCheck specific coverage details for your patient.

Most Common Insurance

Anthem BCBS

Kerendia